DBV Technologies S.A. - 8-K Filing
DBV Technologies provided an update on its Biologics License Application (BLA) for the VIASKIN® Peanut Patch in children aged four through seven years, stating it has been engaged in detailed discussions with the FDA to optimize the review process. The FDA did not request additional data but offered feedback on organizing and formatting existing datasets; DBV now anticipates submitting the BLA in Q3 2026. (Items: 8.01 Other EventsOn June 29, 2026, DBV Technologies S, 9.01 Financial Statements and Exhibits)
Tickers: $DBVT